article29 May 2024 | By Catherine Eckford (European Pharmaceutical Review), Sheldon Sloan (Abivax)
Dr Sheldon Sloan, MBE, Chief Medical Officer, Abivax, shares why the company’s microRNA small molecule treatment could provide long-term efficacy for ulcerative colitis patients, as well as the outlook for using small molecule-based drugs in autoimmune and chronic diseases.